|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 1, 131-142, April 2003
Departments of Biochemistry (Q.S., B.L.R.), Genetics (Q.S.,
J.H.N.), and Nutrition (P.E.), National Institute of Mental Health
Psychoactive Drug Screening Program (J.E.S., S.J.H., L.R., B.L.R.),
School of Medicine, Case Western Reserve University, Cleveland, Ohio;
and Department of Pharmacology (J.T.W., E.G), Georgetown University
Medical Center, Washington, D.C.
Moderate hyperhomocysteinemia is associated with several diseases,
including coronary artery disease, stroke, Alzheimer's disease,
schizophrenia, and spina bifida. However, the mechanisms for their
pathogenesis are unknown but could involve the interaction of
homocysteine or its metabolites with molecular targets such as
neurotransmitter receptors, channels, or transporters. We discovered that L-homocysteine sulfinic acid (L-HCSA),
L-homocysteic acid, L-cysteine sulfinic
acid, and L-cysteic acid are potent and effective agonists
at several rat metabotropic glutamate receptors (mGluRs). These acidic
homocysteine derivatives 1) stimulated phosphoinositide hydrolysis in
the cells stably expressing the mGluR1, mGluR5, or mGluR8 (plus
G
qi9) and 2) inhibited the forskolin-induced cAMP
accumulation in the cells stably expressing mGluR2, mGluR4, or mGluR6,
with different potencies and efficacies depending on receptor subtypes.
Of the four compounds, L-HCSA is the most potent agonist at
mGluR1, mGluR2, mGluR4, mGluR5, mGluR6, and mGluR8. The effects of the
four agonists were selective for mGluRs because activity was not
discovered when L-HCSA and several other homocysteine derivatives were screened against a large panel of cloned
neurotransmitter receptors, channels, and transporters. These findings
imply that mGluRs are candidate G-protein-coupled receptors for
mediating the intracellular signaling events induced by acidic
homocysteine derivatives. The relevance of these findings for the role
of mGluRs in the pathogenesis of homocysteine-mediated phenomena is discussed.
This article has been cited by other articles:
![]() |
J. B. Othersen, J. C. Maize Jr., R. F. Woolson, and M. N. Budisavljevic Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3179 - 3185. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Moshal, U. Sen, N. Tyagi, B. Henderson, M. Steed, A. V. Ovechkin, and S. C. Tyagi Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway Am J Physiol Cell Physiol, March 1, 2006; 290(3): C883 - C891. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chavkin, S. Sud, W. Jin, J. Stewart, J. K. Zjawiony, D. J. Siebert, B. A. Toth, S. J. Hufeisen, and B. L. Roth Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious {kappa}-Opioid Receptor Agonist: Structural and Functional Considerations J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1197 - 1203. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Rothman, N. Vu, J. S. Partilla, B. L. Roth, S. J. Hufeisen, B. A. Compton-Toth, J. Birkes, R. Young, and R. A. Glennon In Vitro Characterization of Ephedrine-Related Stereoisomers at Biogenic Amine Transporters and the Receptorome Reveals Selective Actions as Norepinephrine Transporter Substrates J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 138 - 145. [Abstract] [Full Text] [PDF] |
||||